Provention Bio Inc says Phase 3 trial for diabetes drug candidate to begin in 2Q

Provention Bio Inc (NASDAQ:PRVB) said Tuesday that it expects to begin in the second quarter its Phase 3 trial of a treatment for recent onset Type One diabetes.

The biopharmaceutical company said it has entered into an agreement with Parexel, a clinical research organization, to conduct the study of PRV-031.

The Oldwick, New Jersey, company said recent milestones include the announcement with Amgen Inc (NASDAQ:AMGN) of a licensing and co-development agreement for PRV-015, a monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease.

READ: Kodiak Sciences pushes ahead with trials for diabetic eye disease drug as it unveils 3Q results

“Over the course of 2019, we expect a steady cadence of data readouts from ongoing studies designed to illustrate the potential of our approach,” CEO Ashleigh Palmer said in a statement.

For the fourth quarter, the company reported a

... read more at: https://www.proactiveinvestors.com/companies/news/216790/provention-bio-inc-says-phase-3-trial-for-diabetes-drug-candidate-to-begin-in-2q-216790.html

by